LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,149
تعداد مقالات10,518
تعداد مشاهده مقاله45,415,567
تعداد دریافت فایل اصل مقاله11,291,387
Motamedi Dehbarez, Fatemeh, Mahmoodi, Shirin. (1401). Production of a Novel Multi-Epitope Peptide Vaccine against Hepatocellular Carcinoma. سامانه مدیریت نشریات علمی, 47(6), 558-565. doi: 10.30476/ijms.2021.90916.2199
Fatemeh Motamedi Dehbarez; Shirin Mahmoodi. "Production of a Novel Multi-Epitope Peptide Vaccine against Hepatocellular Carcinoma". سامانه مدیریت نشریات علمی, 47, 6, 1401, 558-565. doi: 10.30476/ijms.2021.90916.2199
Motamedi Dehbarez, Fatemeh, Mahmoodi, Shirin. (1401). 'Production of a Novel Multi-Epitope Peptide Vaccine against Hepatocellular Carcinoma', سامانه مدیریت نشریات علمی, 47(6), pp. 558-565. doi: 10.30476/ijms.2021.90916.2199
Motamedi Dehbarez, Fatemeh, Mahmoodi, Shirin. Production of a Novel Multi-Epitope Peptide Vaccine against Hepatocellular Carcinoma. سامانه مدیریت نشریات علمی, 1401; 47(6): 558-565. doi: 10.30476/ijms.2021.90916.2199

Production of a Novel Multi-Epitope Peptide Vaccine against Hepatocellular Carcinoma

Iranian Journal of Medical Sciences
مقاله 7، دوره 47، شماره 6، بهمن 2022، صفحه 558-565    اصل مقاله (792.39 K)
نوع مقاله: Original Article(s)
شناسه دیجیتال (DOI): 10.30476/ijms.2021.90916.2199
نویسندگان
Fatemeh Motamedi Dehbarez؛ Shirin Mahmoodi*
Department of Medical Biotechnology, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran
چکیده
Background: Hepatocellular carcinoma (HCC) is one of the prevalent cancers in the world with a high recurrence rate. In recent years, different researches have focused on designing efficient multi-epitope peptide vaccines against HCC. In designing these vaccines, over-expressed antigens in HCC patients, such as α- fetoprotein (AFP) and glypican-3 (GPC-3), have been employed. In our previous study, a multi-epitope peptide vaccine for HCC was designed by in-silico methods. The designed vaccine construct included the AFP, GPC-3, and aspartyl-β-hydroxylase (ASPH) as CytoLoxic T cell Lymphocytes (CTL), one epitope from Tetanus Toxin Fragment C (TTFrC) as Helper T cell Lymphocytes (HTL), and a segment of microbial heat shock protein (HSP70) peptide407-426 as an adjuvant. All the mentioned parts were connected by appropriate linkers. The aim of this study is the production of the designed vaccine. 
Methods: This research is experimental and was carried out in Fasa, Iran, in 2017. The designed vaccine construct gene was transformed to the Escherchia coli BL21 (DE3) strain and expressed in different isopropyl β-D-1-thiogalactopyranoside (IPTG) concentrations (0.6 and 1 mM), times (4, 6, 8, 16 hours), and temperatures (25 and 37 °C). Then, the expressed protein was analyzed by Sodium dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and the Western blot methods. 
Results: The best conditions for protein expression were obtained in the Super Optimal Broth (SOB) medium at 37 °C after the induction of expression by 1 mM IPTG for six hour. 
Conclusion: The recombinant HCC vaccine was produced with a proper concentration. 
کلیدواژه‌ها
Hepatocelluar carcinoma؛ Vaccine؛ Subunit؛ Expression؛ Designed
سایر فایل های مرتبط با مقاله
مراجع
  1. Shimada S, Mogushi K, Akiyama Y, Furuyama T, Watanabe S, Ogura T, et al. Comprehensive molecular and immunological characterization of hepatocellular carcinoma. EBioMedicine. 2019;40:457-70. doi: 10.1016/j.ebiom.2018.12.058. PubMed PMID: 30598371; PubMed Central PMCID: PMCPMC6412165.
  2. Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg. 2015;261:947-55. doi: 10.1097/SLA.0000000000000710. PubMed PMID: 25010665.
  3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-90. doi: 10.1056/NEJMoa0708857. PubMed PMID: 18650514.
  4. Johnston MP, Khakoo SI. Immunotherapy for hepatocellular carcinoma: Current and future. World J Gastroenterol. 2019;25:2977-89. doi: 10.3748/wjg.v25.i24.2977. PubMed PMID: 31293335; PubMed Central PMCID: PMCPMC6603808.
  5. Ghahremanifard P, Afzali F, Rostami A, Nayeri Z, Bambai B, Minuchehr Z. Designing a novel multi-epitope T vaccine for “targeting protein for Xklp-2”(TPX2) in hepatocellular carcinoma based on immunoinformatics approach. International Journal of Peptide Research and Therapeutics. 2020;26:1127-36. doi: 10.1007/s10989-019-09915-2.
  6. Nakagawa H, Mizukoshi E, Kobayashi E, Tamai T, Hamana H, Ozawa T, et al. Association Between High-Avidity T-Cell Receptors, Induced by alpha-Fetoprotein-Derived Peptides, and Anti-Tumor Effects in Patients With Hepatocellular Carcinoma. Gastroenterology. 2017;152:1395-406. doi: 10.1053/j.gastro.2017.02.001. PubMed PMID: 28188748.
  7. Tomimaru Y, Mishra S, Safran H, Charpentier KP, Martin W, De Groot AS, et al. Aspartate-beta-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma. Vaccine. 2015;33:1256-66. doi: 10.1016/j.vaccine.2015.01.037. PubMed PMID: 25629522; PubMed Central PMCID: PMCPMC4331251.
  8. Butterfield LH, Economou JS, Gamblin TC, Geller DA. Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients. J Transl Med. 2014;12:86. doi: 10.1186/1479-5876-12-86. PubMed PMID: 24708667; PubMed Central PMCID: PMCPMC4021640.
  9. Yamauchi N, Watanabe A, Hishinuma M, Ohashi K, Midorikawa Y, Morishita Y, et al. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol. 2005;18:1591-8. doi: 10.1038/modpathol.3800436. PubMed PMID: 15920546.
  10. Tsuchiya N, Hosono A, Yoshikawa T, Shoda K, Nosaka K, Shimomura M, et al. Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors. Oncoimmunology. 2017;7:e1377872. doi: 10.1080/2162402X.2017.1377872. PubMed PMID: 29296538; PubMed Central PMCID: PMCPMC5739579.
  11. Jia S, VanDusen WJ, Diehl RE, Kohl NE, Dixon RA, Elliston KO, et al. cDNA cloning and expression of bovine aspartyl (asparaginyl) beta-hydroxylase. J Biol Chem. 1992;267:14322-7. PubMed PMID: 1378441.
  12. Aihara A, Huang CK, Olsen MJ, Lin Q, Chung W, Tang Q, et al. A cell-surface beta-hydroxylase is a biomarker and therapeutic target for hepatocellular carcinoma. Hepatology. 2014;60:1302-13. doi: 10.1002/hep.27275. PubMed PMID: 24954865; PubMed Central PMCID: PMCPMC4176525.
  13. McKee AS, Munks MW, Marrack P. How do adjuvants work? Important considerations for new generation adjuvants. Immunity. 2007;27:687-90. doi: 10.1016/j.immuni.2007.11.003. PubMed PMID: 18031690.
  14. Baek KH, Zhang H, Lee BR, Kwon YG, Ha SJ, Shin I. A small molecule inhibitor for ATPase activity of Hsp70 and Hsc70 enhances the immune response to protein antigens. Sci Rep. 2015;5:17642. doi: 10.1038/srep17642. PubMed PMID: 26631605; PubMed Central PMCID: PMCPMC4668564.
  15. Kelly M, McNeel D, Fisch P, Malkovsky M. Immunological considerations underlying heat shock protein-mediated cancer vaccine strategies. Immunol Lett. 2018;193:1-10. doi: 10.1016/j.imlet.2017.11.001. PubMed PMID: 29129721.
  16. Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol. 2002;20:395-425. doi: 10.1146/annurev.immunol.20.100301.064801. PubMed PMID: 11861608.
  17. Walker KB, Keeble J, Colaco C. Mycobacterial heat shock proteins as vaccines - a model of facilitated antigen presentation. Curr Mol Med. 2007;7:339-50. doi: 10.2174/156652407780831575. PubMed PMID: 17584074.
  18. Xu M, Zhou L, Zhang Y, Xie Z, Zhang J, Guo L, et al. A Fixed Human Umbilical Vein Endothelial Cell Vaccine With 2 Tandem Repeats of Microbial HSP70 Peptide Epitope 407-426 As Adjuvant for Therapy of Hepatoma in Mice. J Immunother. 2015;38:276-84. doi: 10.1097/CJI.0000000000000091. PubMed PMID: 26261891.
  19. Li J, Xing Y, Zhou Z, Yao W, Cao R, Li T, et al. Microbial HSP70 peptide epitope 407-426 as adjuvant in tumor-derived autophagosome vaccine therapy of mouse lung cancer. Tumour Biol. 2016;37:15097-105. doi: 10.1007/s13277-016-5309-2. PubMed PMID: 27662838.
  20. Dehbarez FM, Nezafat N, Mahmoodi S. In Silico Design of a Novel Multi-Epitope Peptide Vaccine Against Hepatocellular Carcinoma. Letters in Drug Design and Discovery. 2020;17:1164-76. doi: 10.2174/1570180817999200502030038.
  21. Chang AY, Chau V, Landas JA, Pang Y. Preparation of calcium competent Escherichia coli and heat-shock transformation. JEMI methods. 2017;1:22-5.
  22. Gravel P, Golaz O. Protein blotting by the semidry method. The protein protocols handbook. New York: Springer; 1996. p. 621-9.
  23. Kim RD, Sarker D, Meyer T, Yau T, Macarulla T, Park JW, et al. First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. Cancer Discov. 2019;9:1696-707. doi: 10.1158/2159-8290.CD-19-0555. PubMed PMID: 31575541.
  24. Villanueva A, Hernandez-Gea V, Llovet JM. Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol. 2013;10:34-42. doi: 10.1038/nrgastro.2012.199. PubMed PMID: 23147664.
  25. Gnoni A, Santini D, Scartozzi M, Russo A, Licchetta A, Palmieri V, et al. Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel? Expert Opin Ther Targets. 2015;19:1623-35. doi: 10.1517/14728222.2015.1071354. PubMed PMID: 26212068.
  26. Herzer K, Hofmann TG, Teufel A, Schimanski CC, Moehler M, Kanzler S, et al. IFN-alpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53. Cancer Res. 2009;69:855-62. doi: 10.1158/0008-5472.CAN-08-2831. PubMed PMID: 19141642.
  27. Palmer DH, Midgley RS, Mirza N, Torr EE, Ahmed F, Steele JC, et al. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumor lysate in patients with hepatocellular carcinoma. Hepatology. 2009;49:124-32. doi: 10.1002/hep.22626. PubMed PMID: 18980227.
  28. Liu YK, Yang KZ, Wu YD, Gang YQ, Zhu DN. Treatment of advanced primary hepatocellular carcinoma by 131-I-anti-AFP. Lancet. 1983;1:531-2. doi: 10.1016/s0140-6736(83)92220-1. PubMed PMID: 6186874.
  29. Sawada Y, Yoshikawa T, Ofuji K, Yoshimura M, Tsuchiya N, Takahashi M, et al. Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients. Oncoimmunology. 2016;5:e1129483. doi: 10.1080/2162402X.2015.1129483. PubMed PMID: 27467945; PubMed Central PMCID: PMCPMC4910752.
  30. Negahdaripour M, Nezafat N, Eslami M, Ghoshoon MB, Shoolian E, Najafipour S, et al. Structural vaccinology considerations for in silico designing of a multi-epitope vaccine. Infect Genet Evol. 2018;58:96-109. doi: 10.1016/j.meegid.2017.12.008. PubMed PMID: 29253673.
  31. Zhang L. Multi-epitope vaccines: a promising strategy against tumors and viral infections. Cell Mol Immunol. 2018;15:182-4. doi: 10.1038/cmi.2017.92. PubMed PMID: 28890542; PubMed Central PMCID: PMCPMC5811687.
  32. Gilboa E. The promise of cancer vaccines. Nat Rev Cancer. 2004;4:401-11. doi: 10.1038/nrc1359. PubMed PMID: 15122211.
  33. Greten TF, Manns MP, Korangy F. Immunotherapy of HCC. Rev Recent Clin Trials. 2008;3:31-9. doi: 10.2174/157488708783330549. PubMed PMID: 18474013.
  34. Pardee AD, Yano H, Weinstein AM, Ponce AA, Ethridge AD, Normolle DP, et al. Route of antigen delivery impacts the immunostimulatory activity of dendritic cell-based vaccines for hepatocellular carcinoma. J Immunother Cancer. 2015;3:32. doi: 10.1186/s40425-015-0077-x. PubMed PMID: 26199728; PubMed Central PMCID: PMCPMC4509479.
  35. Zhou Y, Li C, Shi G, Xu X, Luo X, Zhang Y, et al. Dendritic cell-based vaccine targeting aspartate-beta-hydroxylas represents a promising therapeutic strategy for HCC. Immunotherapy. 2019;11:1399-407. doi: 10.2217/imt-2019-0081. PubMed PMID: 31608722.
  36. Shokouhi H, Farahmand B, Ghaemi A, Mazaheri V, Fotouhi F. Vaccination with three tandem repeats of M2 extracellular domain fused to Leismania major HSP70 protects mice against influenza A virus challenge. Virus Res. 2018;251:40-6. doi: 10.1016/j.virusres.2018.05.003. PubMed PMID: 29730305.
آمار
تعداد مشاهده مقاله: 4,845
تعداد دریافت فایل اصل مقاله: 3,572


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب